肿瘤细胞治疗研究
英文原题：Frontline T cell-redirecting therapies in newly diagnosed multiple myeloma: key signals from the 2025 ASH Annual Meeting.
2025年ASH年会上公布的早期一线数据表明，T细胞重定向策略，包括嵌合抗原受体（CAR）-T细胞和双特异性抗体（BsAbs），可在新诊断多发性骨髓瘤（NDMM）中诱导快速、高比例的微小残留病（MRD）阴性缓解，包括不适合移植（TI）和高危人群。
2025年ASH年会上公布的早期一线数据表明，T细胞重定向策略，包括嵌合抗原受体（CAR）-T细胞和双特异性抗体（BsAbs），可在新诊断多发性骨髓瘤（NDMM）中诱导快速、高比例的微小残留病（MRD）阴性缓解，包括不适合移植（TI）和高危人群。然而，随访时间短、MRD方法学异质性以及感染风险——尤其是持续双特异性抗体暴露——凸显出这些方法仍处于研究阶段，应通过随机、MRD指导的固定疗程试验加以推进。
Early frontline data presented at the 2025 ASH Annual Meeting suggest that T cell-redirecting strategies, including chimeric antigen receptor (CAR)-T cells and bispecific antibodies (BsAbs), can induce rapid, high rates of minimal residual disease (MRD)-negative responses in newly diagnosed multiple myeloma (NDMM), including transplant-ineligible (TI) and high-risk populations. However, short follow-up, heterogeneous MRD methodologies, and infection risk-particularly with continuous bispecific exposure-underscore that these approaches remain investigational and should be advanced through randomized, MRD-guided fixed-duration trials.
MEMBER ACCOUNT
登录成功会直接打开下一页。
